Abstract

Benexate HCl betadex (Ulgut) is a newly introduced antiulcer agent which stimulates production of mucus and enhanced mucosal blood flow on, gastric mucosa. This agent is known to have efficacy in treatment of peptic ulcer. This study was designed to evaluate the efficacy and safety of Benexate HCl betadex in treatment of gastric ulcer. Thirty-three patients with endoscopically diagnosed gastric ulcer were treated with Benexate HCl betadex 400 mg twice daily per os for 4 ar 8 week. Among them 3 patients were excluded due to missed during follow-up in two patients and one with gastric cancer, Every patients were assessed clinically and endoscopically before treatment, at 1 week, 2 weeks, 4 weeks, 6 weeks and 8 weeks after treatment. The result were as follows. 1) The rate of completely healing of gastric ulcer was 36.7% at 4 weeks and 76.7% at 8 weeks after the treatment. 2) Clinical symptoms(epigastric pain) disappeared in 96.7% of patients with gastric ulcer at 1 week. 3) Three patients developed side effects of drug including constipation, skin rash and liver function abnormality, respectively. These results demonstrated that Benexate HCl betadex 400 mg twice daily p.o. could be effective and safe in treatment of gastric ulcer patients.